Nkarta (NKTX) Year-over-year earnings per share growth for the last twelve months

Corporate emblem and logo of Nkarta Corp (NKTX)

The quarterly percentage growth in earnings per share reflects the dynamics of Nkarta, Inc. (NKTX), which develops affordable NK-cell therapies for the treatment of hematological malignancies. The development process is based on leveraging external laboratories while maintaining full ownership of intellectual property rights. High costs associated with safety and patents limit the entry of competitors, with the indicator reaching -52.10.

Nkarta (NKTX) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/16/2026

NKTX (nkartatx.com): analytical breakdowns and indicator data

- market value and analyst target forecast:
Initial company analysis:Nkarta, Inc.
Manufactured product of Nkarta, Inc.

Defensive assets are typically characterized by stable cash flows and predictable returns. Nkarta, Inc. (NKTX) does not meet these criteria, as its value is based on the speculative potential of cancer treatment patents. This quarterly EPS growth rate measures earnings per share dynamics by interpolating infrequent reports into daily values. This calculation reveals seasonal cycles and the rate of change in business efficiency. Analysis of this chart allows for an assessment of how clinical trial results impact the company's fundamental value.

Who Nkarta, Inc. competes with

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Syndax Pharmaceuticals SNDX|Quarterly EPS earnings growth KURA|ADC Therapeutics SA - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth FHTX (Foghorn Therapeutics, Inc.)|Vor Bio Inc. (VOR) - Earnings per share growth in annualized terms for the last twelve months|COEP - Year-over-year earnings per share growth for the last twelve months|Actinium Pharmaceuticals, Inc. (ATNM) - Year-over-year net earnings per share growth for the last 12 months|ESLA (Estrella Immunopharma) - Year-over-year net earnings per share growth for the last 12 months|CASI - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Marker Bio|Quarterly EPS earnings growth IN8bio, Inc.|Year-over-year earnings per share growth for the last twelve months Eterna Therapeutics Inc (ERNA)|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months